Fermenta Biotech Ltd
₹ 320
0.99%
04 Jun
- close price
About
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Key Points
- Market Cap ₹ 941 Cr.
- Current Price ₹ 320
- High / Low ₹ 399 / 249
- Stock P/E 15.9
- Book Value ₹ 144
- Dividend Yield 0.78 %
- ROCE 18.2 %
- ROE 14.8 %
- Face Value ₹ 5.00
Pros
Cons
- The company has delivered a poor sales growth of 3.94% over past five years.
- Company has a low return on equity of 11.5% over last 3 years.
- Earnings include an other income of Rs.30.9 Cr.
- Working capital days have increased from 65.8 days to 122 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 6 | 6 | 13 | 403 | 299 | 371 | 387 | 328 | 307 | 429 | 450 | |
| 11 | 12 | 14 | 22 | 255 | 229 | 276 | 310 | 288 | 269 | 323 | 359 | |
| Operating Profit | 3 | -6 | -8 | -9 | 148 | 70 | 95 | 77 | 39 | 38 | 106 | 91 |
| OPM % | 21% | -99% | -154% | -75% | 37% | 24% | 26% | 20% | 12% | 12% | 25% | 20% |
| 0 | 1 | 0 | 0 | 6 | 12 | 6 | 8 | -51 | -1 | 7 | 31 | |
| Interest | 0 | 2 | 6 | 11 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 11 |
| Depreciation | 2 | 2 | 3 | 4 | 12 | 15 | 19 | 24 | 24 | 24 | 23 | 21 |
| Profit before tax | 1 | -9 | -18 | -23 | 121 | 48 | 63 | 43 | -58 | -5 | 74 | 89 |
| Tax % | 30% | -1% | 2% | 3% | 9% | -34% | 18% | 29% | -2% | 307% | 9% | 28% |
| 1 | -9 | -18 | -24 | 110 | 64 | 52 | 30 | -57 | -19 | 68 | 64 | |
| EPS in Rs | 0.26 | -3.31 | -6.63 | -8.75 | 40.13 | 21.63 | 17.66 | 10.27 | -19.37 | -6.37 | 22.98 | 21.84 |
| Dividend Payout % | 157% | -6% | -3% | -2% | 1% | 23% | 14% | 12% | -6% | -19% | 11% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 4% |
| 3 Years: | 11% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 3% |
| 3 Years: | 168% |
| TTM: | -17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 0% |
| 3 Years: | 32% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
| Reserves | 90 | 80 | 87 | 62 | 245 | 298 | 356 | 382 | 322 | 300 | 365 | 408 |
| 35 | 52 | 44 | 143 | 209 | 226 | 234 | 241 | 219 | 139 | 115 | 113 | |
| 15 | 15 | 12 | 15 | 93 | 71 | 78 | 76 | 108 | 112 | 128 | 116 | |
| Total Liabilities | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 664 | 565 | 622 | 652 |
| 7 | 93 | 94 | 96 | 177 | 197 | 250 | 287 | 257 | 267 | 226 | 220 | |
| CWIP | 63 | 1 | 1 | 0 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 40 | 41 | 40 | 118 | 8 | 1 | 13 | 13 | 15 | 4 | 4 | 12 |
| 33 | 15 | 12 | 9 | 344 | 341 | 363 | 378 | 347 | 293 | 377 | 408 | |
| Total Assets | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 664 | 565 | 622 | 652 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -5 | -9 | 1 | 91 | 30 | 63 | 50 | 124 | 105 | 34 | 83 | |
| -11 | -8 | 20 | -89 | -97 | -39 | -44 | -32 | -63 | -15 | 0 | -44 | |
| 9 | 14 | -13 | 88 | 12 | -48 | -1 | -22 | -41 | -91 | -51 | -42 | |
| Net Cash Flow | -2 | 1 | -2 | 1 | 6 | -57 | 18 | -4 | 19 | -1 | -17 | -4 |
| Free Cash Flow | -28 | -26 | -17 | -3 | 55 | -34 | 8 | 13 | 83 | 86 | 31 | 52 |
| CFO/OP | 40% | 69% | 123% | -22% | 83% | 62% | 81% | 78% | 304% | 276% | 35% | 109% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 5 | 2 | 26 | 8 | 59 | 94 | 95 | 111 | 75 | 92 | 102 | 111 |
| Inventory Days | 347 | 501 | 392 | 328 | 317 | 272 | 249 | 311 | ||||
| Days Payable | 172 | 208 | 135 | 115 | 150 | 184 | 169 | 151 | ||||
| Cash Conversion Cycle | 5 | 2 | 26 | 8 | 234 | 387 | 352 | 324 | 242 | 180 | 182 | 271 |
| Working Capital Days | -923 | -2,525 | -769 | -456 | 42 | 225 | 73 | 92 | -19 | 25 | 51 | 122 |
| ROCE % | 1% | -5% | -9% | -7% | 45% | 13% | 14% | 10% | 4% | 4% | 20% | 18% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover Ratio (Annualized) x |
|
|||||||
| Global Presence (Number of Countries) Number |
||||||||
| Number of Global Customers Number |
||||||||
| Total R&D Expenditure INR Lakhs |
||||||||
| Total Employee Strength Number |
||||||||
| Hazardous Waste Generated (Efficiency Proxy) Metric Tonnes |
||||||||
| Number of Patents Granted (Annual) Number |
||||||||
| Animal Nutrition Segment Volume Growth (YoY) % |
||||||||
| Human Nutrition Segment Volume Growth (YoY) % |
||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 28 May
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 May - Publication of audited financial results for the quarter and financial year ended March 31, 2026.
-
Corporate Action-Board approves Dividend
26 May - Board approved FY26 audited results, 74th AGM on August 11, and final dividend of Rs. 3.75 per share.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 May - Fermenta FY26 consolidated revenue Rs 547.8 crore, EBITDA Rs 122.2 crore, PAT Rs 70.3 crore; dividend Rs 3.75/share.
-
Intimation Under Regulation 30 And Other Applicable Provisions Of SEBI Listing Regulations
26 May - Board approved NSE direct listing application, 3,95,400 ESOPs, and subsidiary private placement plans.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Sep 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022Transcript PPT
-
Jun 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Dec 2021Transcript PPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Dec 2019TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Sep 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than